Ascendis Pharma A/S (ASND) Q4 2022 Results Conference Call February 16, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director of Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President, Chief Financial Officer Stina Singel - Executive Vice President, Head of Clinical Development Oncology Joe Kelly - Senior Vice President, Head of U.S. Commercial Endocrinology Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Da ...

财务表现 - Ascendis Pharma 全年2022年度总收入为 5120 万欧元，较2021年的 778 万欧元增长显著[6] - 研发费用在2022年达到 3.796 亿欧元，较2021年的 2.959 亿欧元有所增加[7] - 销售、一般和管理费用在2022年为 2.212 亿欧元，较2021年的 1.602 亿欧元有所增加[8] - Ascendis Pharma 2022年度净亏损为 5.832 亿欧元，较2021年的 3.836 亿欧元有所增加[10] 资产状况 - Ascendis Pharma 截至2022年12月31日的现金、现金等价物和可市场化证券总额为 7.429 亿欧元，较2021年底的 7.896 亿欧元略有下降[11] - Ascendis Pharma A/S 2022年12月31日的总资产为1,089,738,000欧元，较2021年同期略有增长[20] - 公司2022年12月31日的现金及现金等价物为444,767,000欧元，较2021年同期持平[20] - Ascendis Pharma A/S 2022年12月31日的非流动资产中，投资占比较高，为166,267,000欧元[20] 负债情况 - 公司2022年12月31日的负债总额为826,390,000欧元，较2021年同期大幅增长[20] 股本情况 - Ascendis Pharma A/S 2022年12月31日的股本为7,675,000欧元，较上年略有增长[20]

中国市场表现 - 公司财报电话会议中提到，公司在中国市场创下了iPhone销售收入纪录[110] 产品发展 - 公司表示将继续发展新产品和技术，包括在肿瘤学和眼科领域的产品候选品[7] - 公司强调了对产品和产品候选品的商业化、市场推广和制造能力的期望[7] 全球战略 - 公司计划在全球范围内实施商业模式和战略计划，包括全球商业化策略[8]

R E F. 7 0 4 4 9 - 6 5 1 2 9 Sep t e m b e r 2 0 2 2 E x h i b i t 1 . 1 A r t i c l e s o f A s s o c i a t i o n of A s c e n d i s P h a r m a A / S ( C V R - n r. 2 9 9 1 8 7 9 1 ) (R eg is t r a t i o n n o 2 9 9 1 8 7 9 1) Name, Registered Office and Objects of the Company: Article 1 The company's name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combating of disease medic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ OR ☐ SHELL COMPANY REPORT P ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTI ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTI ...